Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 124-131

  Kato, Tatsuya ^a   Daigo, Yataro ^b   Aragaki, Masato ^b,c   Ishikawa, Keidai ^a   Sato, Masaaki ^d   Kondo, Satoshi ^c   Kaji, Mitsuhito ^a  

^a Sapporo Minami Sanjo Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Sapporo Medical Center   (Japan)

Author keywords

Immunohistochemistry; Lung cancer; MAD2; Mitotic checkpoint; Prognostic factor

Indexed keywords

PROTEIN MAD2;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLEURA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; REPRESSOR PROTEINS; SEX FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80052558778     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.025     Document Type: Article

References (26)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001, 37(Suppl. 7):S63-S73.
3. De Antoni A., Pearson C.G., Cimini D., Canman J.C., Sala V., Nezi L., et al. The Mad1/Mad2 complex as a template for Mad2 activation in the spindle assembly checkpoint. Curr Biol 2005, 15:214-225.
4. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13:1929-1939.
5. Zhang S.H., Xu A.M., Chen X.F., Li D.H., Sun M.P., Wang Y.J. Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Hum Pathol 2008, 39:1827-1834.
6. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
7. Hisaoka M., Matsuyama A., Hashimoto H. Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int 2008, 58:329-333.
8. Yu L., Guo W.C., Zhao S.H., Tang J., Chen J.L. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. Apmis 2010, 118:222-229.
9. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
10. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001, 98:13784-13789.
11. Sotillo R., Hernando E., Diaz-Rodriguez E., Teruya-Feldstein J., Cordon-Cardo C., Lowe S.W., et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007, 11:9-23.
12. Sotillo R., Schvartzman J.M., Socci N.D., Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 2010, 464:436-440.
13. International histological classification of tumours. 3rd ed. Geneva: World Health Organization; 1999.
14. Sobin L., Wittekind Ch. TNM classification of malignant tumours 2002, Wiley-Liss Inc., New York. 6th ed.
15. Nagashio R., Sato Y., Jiang S.X., Ryuge S., Kodera Y., Maeda T., et al. Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 2008, 62:364-373.
16. Nagashio R., Sato Y., Matsumoto T., Kageyama T., Satoh Y., Shinichiro R., et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer 2009, 69:54-59.
17. Weaver B.A., Cleveland D.W. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005, 8:7-12.
18. van Deursen J.M. Rb loss causes cancer by driving mitosis mad. Cancer Cell 2007, 11:1-3.
19. Li Y., Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996, 274:246-248.
20. Nasmyth K. How do so few control so many?. Cell 2005, 120:739-746.
21. Garber P.M., Rine J. Overlapping roles of the spindle assembly and DNA damage checkpoints in the cell-cycle response to altered chromosomes in Saccharomyces cerevisiae. Genetics 2002, 161:521-534.
22. Mikhailov A., Cole R.W., Rieder C.L. DNA damage during mitosis in human cells delays the metaphase/anaphase transition via the spindle-assembly checkpoint. Curr Biol 2002, 12:1797-1806.
23. Fung M.K., Han H.Y., Leung S.C., Cheung H.W., Cheung A.L., Wong Y.C., et al. MAD2 interacts with DNA repair proteins and negatively regulates DNA damage repair. J Mol Biol 2008, 381:24-34.
24. Dobles M., Liberal V., Scott M.L., Benezra R., Sorger P.K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000, 101:635-645.
25. Michel L.S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W., et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001, 409:355-359.
26. Hernando E., Nahle Z., Juan G., Diaz-Rodriguez E., Alaminos M., Hemann M., et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004, 430:797-802.